225 related articles for article (PubMed ID: 37016732)
21. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
22. A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
Rubinstein MM; Grisham RN; Cadoo K; Kyi C; Tew WP; Friedman CF; O'Cearbhaill RE; Zamarin D; Zhou Q; Iasonos A; Nikolovski I; Xu H; Soldan KN; Caird I; Martin M; Guillen J; Eid KT; Aghajanian C; Makker V
Gynecol Oncol; 2021 Jan; 160(1):71-76. PubMed ID: 33139041
[TBL] [Abstract][Full Text] [Related]
23. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
[TBL] [Abstract][Full Text] [Related]
24. A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.
Twelves C; Anthoney A; Savulsky CI; Guo M; Reyderman L; Cresti N; Semiglazov V; Timcheva C; Zubairi I; Morrison R; Plummer R; Evans TRJ
Br J Cancer; 2019 Mar; 120(6):579-586. PubMed ID: 30783204
[TBL] [Abstract][Full Text] [Related]
25. Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
Rinnerthaler G; Gampenrieder SP; Petzer A; Burgstaller S; Fuchs D; Rossmann D; Balic M; Egle D; Rumpold H; Singer CF; Bartsch R; Petru E; Melchardt T; Ulmer H; Mlineritsch B; Greil R
BMC Cancer; 2018 Nov; 18(1):1074. PubMed ID: 30400780
[TBL] [Abstract][Full Text] [Related]
26. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
28. Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma.
Mittal S; Kadamberi IP; Chang H; Wang F; Kumar S; Tsaih SW; Walker CJ; Chaluvally-Raghavan P; Charlson J; Landesman Y; Pradeep S
Exp Hematol Oncol; 2023 Sep; 12(1):78. PubMed ID: 37715291
[TBL] [Abstract][Full Text] [Related]
29. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
Zhang Q; Shao B; Tong Z; Ouyang Q; Wang Y; Xu G; Li S; Li H
BMC Med; 2022 Oct; 20(1):321. PubMed ID: 36184642
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models.
Guo Z; Luo J; Mashl RJ; Hoog J; Maiti P; Fettig N; Davies SR; Aft R; Held JM; Govindan R; Ding L; Li S; von Morze C; Wulf GM; Shoghi KI; Ma CX
Cancer Res Commun; 2024 Jun; 4(6):1430-1440. PubMed ID: 38717161
[TBL] [Abstract][Full Text] [Related]
31. A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers.
Roviello G; Milani M; Gobbi A; Cappelletti MR; Zanotti L; Senti C; Bottini A; Strina C; Sigala S; Generali D
Clin Breast Cancer; 2016 Jun; 16(3):e57-9. PubMed ID: 26943987
[TBL] [Abstract][Full Text] [Related]
32. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
[TBL] [Abstract][Full Text] [Related]
33. Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
Iwasa T; Tsurutani J; Watanabe S; Kato R; Mizuno Y; Kojima Y; Takashima T; Matsunami N; Morimoto T; Yamamura J; Ohtani S; Tanabe Y; Yoshinami T; Takano T; Komoike Y; Nakagawa K
BMC Cancer; 2019 Oct; 19(1):962. PubMed ID: 31619197
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.
Locatelli MA; Aftimos P; Dees EC; LoRusso PM; Pegram MD; Awada A; Huang B; Cesari R; Jiang Y; Shaik MN; Kern KA; Curigliano G
Oncotarget; 2017 Jan; 8(2):2320-2328. PubMed ID: 27906684
[TBL] [Abstract][Full Text] [Related]
35. A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes.
Li Q; Li Q; Zhang P; Yuan P; Wang J; Ma F; Luo Y; Fan Y; Cai R; Xu B
Cancer Biol Ther; 2015; 16(12):1746-53. PubMed ID: 26466918
[TBL] [Abstract][Full Text] [Related]
36. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
37. First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.
Abdul Razak AR; Mau-Soerensen M; Gabrail NY; Gerecitano JF; Shields AF; Unger TJ; Saint-Martin JR; Carlson R; Landesman Y; McCauley D; Rashal T; Lassen U; Kim R; Stayner LA; Mirza MR; Kauffman M; Shacham S; Mahipal A
J Clin Oncol; 2016 Dec; 34(34):4142-4150. PubMed ID: 26926685
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.
Dent RA; Lindeman GJ; Clemons M; Wildiers H; Chan A; McCarthy NJ; Singer CF; Lowe ES; Watkins CL; Carmichael J
Breast Cancer Res; 2013; 15(5):R88. PubMed ID: 24063698
[TBL] [Abstract][Full Text] [Related]
39. A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Curigliano G; Shapiro GI; Kristeleit RS; Abdul Razak AR; Leong S; Alsina M; Giordano A; Gelmon KA; Stringer-Reasor E; Vaishampayan UN; Middleton M; Olszanski AJ; Rugo HS; Kern KA; Pathan N; Perea R; Pierce KJ; Mutka SC; Wainberg ZA
Br J Cancer; 2023 Jan; 128(1):30-41. PubMed ID: 36335217
[TBL] [Abstract][Full Text] [Related]
40. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.
Ruiz-Borrego M; Jimenez B; Antolín S; García-Saenz JA; Corral J; Jerez Y; Trigo J; Urruticoechea A; Colom H; Gonzalo N; Muñoz C; Benito S; Caballero R; Bezares S; Carrasco E; Rojo F; Martín M
Invest New Drugs; 2019 Feb; 37(1):98-108. PubMed ID: 29948356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
